

**Commonwealth of Massachusetts
Department of Developmental Services
Research Review Committee Meeting Minutes
Date: February 7, 2025**

By Teams: Erin Brown (Chairperson), Patricia Shook, Joshua Greenberg, Joseph Meyer, Joseph Weru, Deborah Dreyfus, Janet George, and Freddy Torbey (observer/minutes)

Additional Attendees: Sofia Langman

Agenda Items

1. Administrative matters
2. “A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) with Fragile X Syndrome”, Isha Jalnapurkar, MD, UMass Chan Medical School
3. “Mitigation of Countercontrol Behavior: A Review of Case Studies”, Joseph Tacosik, M.A., BCBA, LABA

HOUSEKEEPING

- ☐ Chair established quorum
- ☐ Chair summarized requirements for approval of research proposals pursuant to 115 CMR 10.08
- ☐ Chair re-presented proposals for discussion
- ☐ Due to professional connections to researcher involved in first proposal, Joshua Greenberg notified that he would abstain from voting
- ☐ RRC discussed conflict of interest rules and behaviors, as well as potential sufficiency of appropriate disclosure followed by objective and rigorous review
- ☐ After RRC discussion, Joshua Greenberg’s voting abstention was rescinded

Review and Vote on January 17, 2025, Meeting Minutes

Outcome

- ☐ Chair presented proposed amendments for January 17, 2025, meeting minutes
- ☐ Chair moved for a vote and Committee members agreed to adopt amended January 17, 2025, meeting minutes (Janet George abstained due to absence)

“A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) with Fragile X Syndrome”, Isha Jalnapurkar, MD, UMass Chan Medical School

Discussion

- ☐ Chair noted that researcher was contacted pursuant to January 17, 2025 meeting, but RRC has not yet received a response

- RRC discussed that despite its psychiatry-focused nature, proposal uses psychological metrics and RRC questioned whether there was involvement by psychologist
- RRC discussed Massachusetts regulatory requirements and RRC duties vis-à-vis pharmaceutical corporations' market and nation-wide focus

Outcome

- Chair moved, and RRC members voted to approve with conditions, namely the submission of informed consent form, as well as compliance with DDS regulations 115 CMR 10.08(2)-(4)

CONDITIONALLY APPROVED PROPOSALS

“A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) with Fragile X Syndrome”, Isha Jalnapurkar, MD, UMass Chan Medical School

CLOSING MATTERS

Discussion of second proposal is deferred for next scheduled RRC meeting on March 7, 2025.